- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Drug discovery - Articles and news items
Supplier news / 25 January 2016 / Tecan
Tecan has launched the Spark® 20M multimode microplate reader, offering tailor-made solutions to suit virtually any drug discovery or advanced life science research application…
Supplier news / 12 January 2016 / DiscoveRx
DiscoveRx Corporation announces the expansion of its PathHunter® cell-based assays portfolio with the release of PathHunter Interleukin cell-based assays…
Supplier news / 14 October 2015 / BioTek
BioTek is excited to introduce the new Cytation™ 5 Cell Imaging Multi-Mode Reader…
Supplier news / 14 October 2015 / BioTek
BioTek introduces Synergy Neo2 high performance Multi-Mode Microplate Reader…
Whitepaper: Development and optimization of CHOgro® transient expression technologies for high titer antibody production in suspension CHO cells
Whitepapers / 1 October 2015 / Mirus Bio
During early stage drug development, quickly obtaining relevant candidate proteins through transient transfection can accelerate drug discovery…
Webinars / 1 July 2015 / Cisbio Bioassays & Trevena, Inc.
TRV027 is a biased ligand; the in vitro profile and its translation into in vivo pharmacology is discussed during this webinar.
Industry news / 8 January 2015 / Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA…
Issue 6 2014 / 23 December 2014 / Paul McCracken & Stephen Krause
In this review, we highlight a few of the ways in which Eisai is attempting to address the research and development bottleneck by adding fit-for-purpose imaging biomarkers to discovery and early development programs for decision making…
Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery…
Proteases: How naturally occurring inhibitors can facilitate small molecule drug discovery for cysteine proteases
Cysteine proteases are expressed ubiquitously in the animal and plant kingdom and are thought to play key roles in maintaining homeostasis. The aberrant function of cysteine proteases in humans are known to lead to a variety of epidermal disease states such as inflammatory skin disease. In marked contrast, the serine proteases have been most widely implicated in disease states, including hypertension, periodontisis, AIDS, thrombosis, respiratory disease, pancreatitis and cancer, and a number of their inhibitors have been approved for clinical use.
Raman spectroscopy has emerged as the preeminent analytical tool for a number of applications within drug discovery and development. Advances in the instrumentation, sensor fabrication and data analysis have enabled the wider acceptance of Raman spectroscopy. In discovery, Raman spectroscopy is used to elucidate structural activity relationships and to optimise reaction conditions and associated parameters (such as polymorph and formulation screening) that impact scale-up required for the transfer of drug compounds from discovery to development.
G protein-coupled receptors are one of the major classes of therapeutic targets for a broad range of diseases. The most commonly used assays in GPCR drug discovery measure production of second messengers such as cAMP or IP3 that are the result of activation of individual signalling pathways. Such specific assays are unable to provide a holistic view of the cell response after GPCR activation. This is now changing as label-free technologies and assays on whole cells have been developed that are unbiased towards the specific downstream pathways and capture the integrated cell response. In this mini-review, we focus on the application of one of these technologies, namely resonant waveguide grating (RWG) for measurements of dynamic mass redistribution (DMR) in intact cells upon GPCR activation. Since the technology is sensitive and non-invasive, it is applicable to most cell types, including primary cells with native receptor expression levels. We discuss how DMR assays have become an important component of GPCR drug discovery screening cascades and may have the potential to improve the ability to predict if compounds will be efficacious in vivo.
ABB Analytical Measurement ABL&E Group ABS Laboratories ACD/Labs Analytik Jena AG Andor Technology Axis-Shield Diagnostics Ltd Bachem AG Bio-Rad Laboratories Biopharma Group CAMO Software AS Celsis International ChemAxon Cherwell Laboratories CI Precision Cobalt Light Systems Comark Instruments Coulter Partners DiscoveRx Edinburgh Instruments Enterprise System Partners EUROGENTEC HunterLab IDBS IONICON Analytik GmbH L.B. Bohle Maschinen + Verfahren GmbH LabWare Linkam Scientific Instruments Limited MKS Umetrics Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc Portalis Ltd Powder Systems Limited (PSL) RADWAG Reach Separations ReAgent Source BioScience Spectrum®Labs.com Stratech Scientific Limited Takara Clontech Thermal Detection Ltd. Vaisala Ltd VIAVI OSP Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Ytron-Quadro (UK) Limited Yusen Logistics